期刊文献+

AmpC酶介导的铜绿假单胞菌耐药研究 被引量:6

Study on resistance of Pseudomonas aeruginosa mediated by AmpC β-lactamases
下载PDF
导出
摘要 目的了解AmpC酶在铜绿假单胞菌对β-内酰胺类抗生素耐药机制中所起的作用。方法选取同一患者治疗前后临床分离株,随机扩增多态性DNA(RAPD)对菌株进行基因分型,微量稀释法测定细菌对头孢他啶的最低抑菌浓度(MIC),头孢西丁三相试验和头孢西丁诱导试验检测AmpC酶产生情况。结果8组铜绿假单胞菌的RAPD分型完全一致,抗生素治疗后分离株对头孢他啶的MIC值较治疗前增加≥8倍,抗生素治疗前分离株头孢西丁三相试验均为阴性,其中6株菌株头孢西丁诱导试验阳性,而治疗后的分离株头孢西丁三相试验均呈阳性。结论β-内酰胺类抗生素治疗失败与AmpC酶被诱导后持续高产有关,对诱导高产酶阳性株引起的感染要避免使用AmpC酶的强诱导剂。 Objective To investigate the production of AmpC β-lactamase and its role in resistance to β-lactam in clinical isolates of Pseudomonas aeruginosa. Methods Pairs ofPseudomonas aeruginosa before and after treatment with antibiotics isolated from the same patient were genotyped by random amplified polymorphic DNA (RAPD). Minimum inhibitory concentrations (MICs)were determined by micro-dilution broth method. Cefoxitin induced test and cefoxitin 3-dimensional test were performed to detect AmpC β-lactamase. Results RAPD profiles of eight pairs of Pseudomonas aeruginosa were exactly the same. MIC to ceftazidime equal or increased greater than eight times after treatment. Cefoxitin induced test were positive in six strains isolated before treatment. Cefoxitin 3- dimensional test were negative in all strains isolated before treatment but were positive in all strains isolated after treatment. Conclusions Failure of treatment with β-lactams was associated with the overproducing of AmpC β- lactamase. β-1actams that can induced the production of AmpC β-lactamase can not be chosen for infection caused by hyperinducible Pseudomonas aeruginosa strains producing AmpC β-lactamase.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2009年第7期441-444,共4页 Chinese Journal of Antibiotics
基金 国家自然科学基金青年科学基金项目(30801403) 汕头市重点科技计划项目(2007)
关键词 AMPC酶 铜绿假单胞菌 耐药 AmpC β-lactamase Pseudomonas aeruginosa Resistance
  • 相关文献

参考文献10

  • 1Mahenthiralingam E,Campbell M E,Foster J,et al.Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis[J].J Clin Microbiol,1996,34(5):1129~1135.
  • 2王扬,夏丽萍,康健,李艳玲,王琨,阎雪.β-内酰胺类抗菌药物对阴沟肠杆菌AmpC酶的诱导性研究[J].中华医院感染学杂志,2007,17(2):125-128. 被引量:13
  • 3沈定树,周雪艳,袁远,徐玖飞,陈慧红,夏东,齐娟飞,陈东.肠杆菌诱导型AmpC酶对第三代和第四代头孢菌素的影响[J].中国微生态学杂志,2006,18(5):384-385. 被引量:9
  • 4Platonov A E,Shipulin G A,Platonov O V.Muhiocus sequencing-a new method of genotyping bacteria and first results of its use[J].Genetika,2000,36(5):597~605.
  • 5Tang Y,Van Graevenitz A,Waddingtong M G,et al.Identification of coryneform bacterial isolates by ribosomal DNA sequence analysis[J].J Clin Microbiol,2000,38 (4):1676~1678.
  • 6陈瑞,唐英春,朱家馨,李建国.耐亚胺培南铜绿假单胞菌外膜蛋白D基因突变检测[J].中华传染病杂志,2006,24(2):80-83. 被引量:7
  • 7Jones R N.Important and emerging bota-lactamase-mediated resistances in hospital-based pathogens:the Amp C enzymes[J].Diagn Microbiol Infect Dis,1998,31(3):461~466.
  • 8Juan C,Macia M D,Gutierrez O,et al.Molecular mechanisms of bota-lactam resistance mediated by AmpC hyperproduction in Pseudomonus aeruginosa clinical strains[J].Antimicrob Agents Chemother,2005,49(11):4733~4738.
  • 9Sanders C C.Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics[J].Annu Rev Microbiol,1987,41:573~593.
  • 10Coudron P E,Moland E S,Thomson K S.Occurrence and detection of AmpC bota-lactamase among Escherichia coli,Klebsiella pneumoniae,and Proteus mirabilis isolataes at a veterans medical center[J].J Clin Microbiol,2000,38 (5):1791~1796.

二级参考文献12

共引文献26

同被引文献52

  • 1姚齐龙.铜绿假单胞菌医院内感染的临床特征及耐药性[J].现代预防医学,2004,31(6):891-892. 被引量:4
  • 2孙茜,王鹏华,李代清.糖尿病足多重耐药铜绿假单胞菌感染情况及危险因素分析[J].中华临床感染病杂志,2012,5(1):15-18. 被引量:7
  • 3王豫平,王慕云,廖致红.多重耐药铜绿假单胞菌感染相关因素分析[J].中华医院感染学杂志,2006,16(9):1059-1060. 被引量:59
  • 4朱欣,李闻文.糖尿病足感染的病原菌特点及耐药性分析研究[J].实用预防医学,2007,14(4):1183-1185. 被引量:8
  • 5金有豫.药理学[M].北京:人民卫生出版社,2002.259-263.
  • 6Yan J J, Hsueh P R, Lu J J, et al. Characterization ofacquired [3-1actamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of umLsual integrons[J]. JAntimicrob Chemother, 2006, 58(3): 530-536.
  • 7Zhao W H, Hu Z Q. Beta-lactamases identified in clinical isolates of Pseudomonas aentginosa [J]. Crit Rev Microbiol, 2010, 36 (3): 245-258.
  • 8Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing ; Twentieth informational supplement. CLSI/NCCLS document M100-S20. Pennsylvania: Clinical and Laboratory Standards Institute, 2010, 20-143.
  • 9Coudron P E, Moland E S, Thomson K S. Occurrence and detection of AmpC 13-1actamases among Escherichia coli, Klebsiella pneumoniae, and proteus mirabilis at a veterans medical center[J]. J Clin Microbiol, 2000, 38: 1791-1796.
  • 10Schmidtke A J, Hanson N E,. Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance[J]. Antimicrob Agents Chemother, 2006, 50(6): 2030-2037.

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部